Loading...
ROCO
4130
Market cap94mUSD
Jul 09, Last price  
27.85TWD
1D
1.83%
1Q
-18.21%
Jan 2017
-24.32%
IPO
127.53%
Name

Genovate Biotechnology Co Ltd

Chart & Performance

D1W1MN
ROCO:4130 chart
P/E
260.75
P/S
6.19
EPS
0.11
Div Yield, %
0.35%
Shrs. gr., 5y
5.94%
Rev. gr., 5y
0.82%
Revenues
492m
-3.61%
465,756,000472,723,000434,254,000438,759,000528,512,000510,856,000492,406,000
Net income
12m
-54.54%
34,055,00038,731,000372,000-12,323,00029,334,00025,698,00011,682,000
CFO
44m
-20.55%
44,432,00087,079,000-17,259,0001,510,00084,782,00055,112,00043,789,000
Dividend
Aug 20, 20250.0980392 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Genovate Biotechnology Co., Ltd. is a Taiwanese enterprise dedicated to the research, development, production, and commercialization of various products. These offerings primarily aim to prevent and treat illnesses resulting from viral and bacterial infections. The company's diverse portfolio extends to drugs, active pharmaceutical ingredients (APIs), intermediates, and specialized release agents, which are crucial for addressing a range of health issues including cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune conditions. Complementing its pharmaceutical offerings, Genovate also manufactures controlled-release Western medicine formulations and cosmetic items. Established in 1982, the company's operations are headquartered in Hsinchu City, Taiwan.
IPO date
Feb 10, 2003
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT